{
    "symbol": "CMPS",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-28 13:09:05",
    "content": " Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. So like everyone, we're intrigued by some of the data that's emerging from shorter-acting, but until it's been validated in much larger studies and in particular some of these questions around durability that we're attempting to answer in Phase 3 are answered by other molecules, other mechanisms it's kind of too early to say how the field will shake out. One moment for our next question. Your line is open. One moment for our next question. Your line is open. And then lastly, on the operating side, we've been very disciplined in the way that we've grown the company really since we announced the Phase 2 results at the end of 2021 and really have just focused on making sure we prepare and start to execute on the Phase 3 as well as our two advanced Phase 2 programs and really have dated all further investments on being able to continue to have a strong balance sheet and the long runway. One moment for our next question. Your line is open. One moment for our next question. Your line is open. Your line is open."
}